Skip to main content
Fig. 1 | Respiratory Research

Fig. 1

From: Metabolomic changes related to airway inflammation, asthma pathogenesis and systemic activity following inhaled fluticasone furoate/vilanterol: a randomized controlled trial

Fig. 1

Time-course of anti-inflammatory activity of FF/VI. Figure reproduced with permission from Bardsley et al. Respir Res. 2018;19(1):133. Mean exhaled nitric oxide (ppb), during treatment and after cessation of treatment, plotted over time, for placebo (grey line) and FF/VI (black line). Error bars denote the standard error. FF/VI, fluticasone furoate/vilanterol trifenatate; ppb, parts per billion

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us